The gene editing company expects to raise up to $90m, while Novartis and Regeneron are set to invest $55m through private placements.
Intellia Therapeutics, a US-based genomic drug developer backed by pharmaceutical companies Regeneron and Novartis, set the range for its initial public offering between $16 and $18 per share on Wednesday.
The company is set to issue five million shares on Nasdaq, which would generate proceeds of $80m to $90m depending on the final share price.
Underwriters Credit Suisse Securities (USA), Jefferies, Leerink Partners and Wedbush Securities have a 30-day option to buy an additional 750,000 shares, which would increase…
